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Available online 24 April 2012Abstract Human embryonic stem cells (hESCs) can self-renew and become all three germ layers. Nodal/Activin signaling
specifies developmental status in hESCs: moderate Nodal/Activin signaling maintains pluripotency, while enhancement and
inhibition promote definitive endoderm (DE) and neuroectoderm (NE) development, respectively. However, how modulation of
Nodal/Activin signaling influences developmental competence and commitment toward specific lineages is still unclear. Here,
we showed that enhancement of Nodal/Activin signaling for 4 days was necessary and sufficient to upregulate DE markers,
while it diminished the upregulation of NE markers by inhibition of Nodal/Activin signaling. This suggests that after 4 days of
enhanced Nodal/Activin signaling, hESCs are committed to the DE lineage and have lost competence toward the NE lineage. In
contrast, inhibition of Nodal/Activin signaling using LY364947 for 2 days was sufficient to impair competence toward the DE
lineage, although cells were still able to activate LEFTY1 and NODAL, direct targets of Nodal/Activin signaling. Expression
analyses indicated that the levels of pluripotency regulators NANOG and POU5F1 were significantly diminished by 2 days of
LY364947 treatment, although the expression of NANOG, but not POU5F1, was restored immediately upon Activin A treatment.
Thus, downregulation of POU5F1 coincided with the abrogation of DE competence caused by inhibition of Nodal/Activin
signaling.
© 2012 Elsevier B.V. All rights reserved.Introduction
Pluripotency is defined as the ability to give rise to derivatives
of all three germ layers, namely ectoderm, mesoderm, and
endoderm. Several types of pluripotent stem cell lines have
been established, such as embryonic stem cells (ESCs), epiblast
stem cells (EpiSCs), and embryonal germ cells (EGCs). These⁎ Corresponding author at: 651 Ilalo Street, Biomedical Sciences
Building 163A, Honolulu, HI 96813, USA. Fax: +1 808 692 1962.
E-mail address: marikawa@hawaii.edu (Y. Marikawa).
1873-5061/$ - see front matter © 2012 Elsevier B.V. All rights reserved.
doi:10.1016/j.scr.2012.04.002pluripotent stem cell lines are derived from specific groups of
pluripotent embryonic tissues. ESCs, EpiSCs, and EGCs originate
from the inner cell mass (ICM) of the blastocyst, the epiblast of
the post-implantation embryo, and the primordial germ cell,
respectively (Pera et al., 2000; Brons et al., 2007; Yu and
Thomson, 2008). Pluripotent stem cells can be maintained and
propagated in vitro for an extended period while retaining
various developmental properties of the original pluripotent
embryonic tissues. In addition, non-pluripotent somatic cells
can also be reprogrammed into pluripotent stem cells, or
induced pluripotent stem cells (iPSCs), by introduction of
defined factors, which exhibit developmental ability similar to
490 K.L. Jaremko, Y. MarikawaESCs or EpiSCs (Takahashi and Yamanaka, 2006; Lowry and
Plath, 2008; Park et al., 2008; Yu et al., 2007).
Pluripotent stem cells can differentiate into various types
of cells in response to distinct environments. Differentiation
can take place in semi-in vivo conditions, such as chimeriza-
tion with a developing embryo or transplantation into an adult
body, the latter of which typically gives rise to teratoma,
containing differentiated tissues of all three germ layers.
Differentiation of pluripotent stem cells can also be induced in
vitro by culturing in specific media. Directed differentiation of
pluripotent stem cells, particularly of human ESCs (hESCs), into
desired cell types in vitro is of medical importance, because
differentiated cells can be used for cell replacement therapy,
drug screening, and investigations into disease pathogenesis
(Zhu et al., 2011; Gearhart, 1998). Thus, many studies have
been focusing on establishing culture conditions and protocols
that enable differentiation of specific cell types from hESCs.
During the course of directed differentiation, pluripotent
stem cells become committed to adopting specific develop-
mental pathways and lose the competence to take on other
pathways. Acquisition of commitment and loss of compe-
tence are the fundamental aspects of embryogenesis.
Namely, the fertilized egg is a single cell that is competent
to give rise to all cell types in the body, but after a series of
cell divisions, individual cells receive distinct developmental
instructions, such as inductive signals, and gradually become
committed towards specific developmental lineages while
the competence to undertake the other lineages is lost. The
concept of developmental commitment and competence
has served as the foundation of classic as well as modern
Developmental Biology to describe the process of animal
development (Waddington, 1940; Wolpert and Tickle, 2010;
Gilbert, 2010). Studies utilizing pluripotent stem cells offer
invaluable opportunities to elucidate in depth the molecular
mechanisms of developmental commitment and competence.
This is especially important for studyingmechanisms of human
development, as the manipulation of early human tissues is
not as accessible as other animal models. An understanding of
how these events are regulated is also significant from the
viewpoint of medical applications of pluripotent stem cells,
especially for cell replacement therapy. One of the concerns
associated with transplantation of cells that are derived from
pluripotent stem cells into patients is that transplants may
contain cells that are not fully committed to desired cell types
and are still competent to give rise to other unwanted
cell types. Any uncommitted pluripotent stem cells that are
included in the transplants are likely to give rise to teratoma in
the patients (Blum and Benvenisty, 2008; Fong et al., 2010;
Ben-David and Benvenisty, 2011).
Nodal/Activin signaling is an evolutionarily conserved signal
transduction pathway, and plays critical roles in the mainte-
nance and differentiation of hESCs. Nodal and Activin (Activin A
and Activin B [Thompson et al., 2004]) are members of the
transforming growth factor beta (TGFβ) superfamily, and bind
to heteromeric complexes between type I (Alk4, Alk5, and Alk7)
and type II (ActRIIB) activin receptors, which in turn activate
Smad2/3 to regulate the expressions of various target genes
(Schier, 2003; Valdimarsdottir and Mummery, 2005; Payne
et al., 2011). Moderate activation of Nodal/Activin signaling is
essential for the maintenance of pluripotency in hESCs (Beattie
et al., 2005; James et al., 2005; Vallier et al., 2005). A small
amount (e.g.,10 ng/mL) of Activin A or TGFβ1 is an essentialingredient in the chemically defined culture media that are
formulated for routinemaintenance of hESCs under feeder-free
conditions (Amit et al., 2004; Brons et al., 2007; Ludwig et al.,
2006). Inhibition of Nodal/Activin signaling with small molecule
inhibitors of Alk4, Alk5, and Alk7, such as SB431542 (Callahan
et al., 2002; Inman et al., 2002) or LY364947 (Sawyer et al.,
2003; Peng et al., 2005), downregulates the expressions of
pluripotency regulators NANOG and OCT4 (POU5F1) in hESCs
(James et al., 2005). Concomitantly, inhibition of Nodal/Activin
signaling directs hESCs toward the neuroectoderm (NE) lineage,
and upregulates the expression of NE marker genes, such as
PAX6, GBX2, and NFH (Wassarman et al., 1997; Camus et al.,
2006; Smith et al., 2008; Patani et al., 2009; Chng et al., 2010;
Hu et al., 2010; Zhou et al., 2010). NE differentiation can be
promoted by a pharmacological inhibitor of Nodal/Activin
signaling, such as SB431542, or by ectopic expression of Nodal
antagonists, such as Lefty2 and Cer-S (Smith et al., 2008; Patani
et al., 2009), whereas it is inhibited by overexpression of NODAL
(Vallier et al., 2004). On the other hand, a high level (e.g.,
50 ng/mL) of Activin A promotes the differentiation of hESCs
into the definitive endoderm (DE) lineage, which is character-
ized by the expression of SOX17, CXCR4, and FOXA2 (D'Amour
et al., 2005; Borowiak et al., 2009; Mayhew and Wells, 2010;
Sulzbacher et al., 2009; Wang et al., 2011). Thus, the level of
Nodal/Activin signaling imposes critical impacts on hESCs, and
regulates three distinct developmental states: a low level or
absence of signaling for the NE lineage, an intermediate level
for the maintenance of pluripotency, and a high level for the
DE lineage. However, the mechanisms of how and when each
developmental state is determined by a specific level of Nodal/
Activin signaling are still not well-understood. For example,
questions like how long hESCs need to be exposed to a high level
of Activin A to become committed toward the DE lineage, and
at what point hESCs lose competence to undertake the DE
lineagewhen Nodal/Activin signaling is inhibited, have not been
addressed.
In the present study, we conducted a series of exper-
iments to gain insight into the regulation of competence and
commitment towards the DE lineage in hESCs. We found that
the duration of exposure to a high level of Activin A had a
cumulative effect on the activation of the DE marker genes
up to 6 days of culture. When hESCs were exposed to Activin
A for 4 days, the inhibition of Nodal/Activin signaling was no
longer able to downregulate the expression of DE markers,
suggesting that hESCs had already become committed to the
DE lineage. We also showed that the commitment toward DE
was associated with the loss of competence toward NE.
To investigate the nature of the competence toward DE,
we tested 5 different pharmacological inhibitors of Nodal/
Activin signaling. While all of them strongly inhibited
Nodal/Activin signaling, only LY364947 was fully reversible,
with the property to be washed way without impairing
activation of Nodal/Activin signaling in response to Activin
A treatment. By taking advantage of the reversible nature
of LY364947, we determined that 2 days, but not 1 day, of
Nodal/Activin signaling inhibition was detrimental to the
DE competence. Finally, we showed that the downregula-
tion of POU5F1 coincided with the loss of DE competence
in response to Nodal/Activin signaling inhibition, raising
the possibility that this key pluripotency regulator plays a
critical role in maintaining the competence toward DE in
hESCs.
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Enhancement and inhibition of Activin signaling in
hESCs promotes DE and NE, respectivelySince the first establishment of hESC lines from human
blastocysts (Thomson et al., 1998), methods have been created
for the induction of differentiation toward all three germ layers
(ectoderm, mesoderm, and endoderm). Specifically, a high
dosage of recombinant Activin A in a low-serum culture
medium has been used to induce definitive endoderm (DE)
(D'Amour et al., 2005; Borowiak et al., 2009), whereas the
inhibition of Nodal/Activin signaling using a chemical inhibitor,
such as SB431542, has been used to promote neuroectoderm
(NE) formation in hESCs (Smith et al., 2008; Patani et al.,
2009). In the present study, we first examined whether
activation or inhibition of Nodal/Activin signaling is sufficient
to promote the DE or NE lineage in the same basal medium.
Undifferentiated hESCs were treated for 6 days with a high
dose of Activin A (50 ng/mL) or SB431542 (10 μM) added to the
basal medium. When cultured with Activin A for 6 days, the
expression of the DE markers, SOX17, FOXA2, and CXCR4, were
significantly activated, as compared to culture in the basal
medium only. On the other hand, when treated with SB431542
in the same basal medium for 6 days, there was a significant
increase in the expression of the NE markers, PAX6, GBX2, and
NFH (Figure 1A). In mouse embryos, Gbx2 is expressed in the
primitive streak, from which DE emerges (Wassarman et al.,
1997; Waters et al., 2003). In hESC differentiation, however,
GBX2was expressed only in SB431542-treated but not in Activin
A-treated cells (FIG. S1). This suggests that GBX2 is mainly
activated in the NE lineage but not in the DE lineage, consistent
with previous reports (Chng et al., 2010; Camus et al., 2006; Hu
et al., 2010; Patani et al., 2009; Wassarman et al., 1997). The
basal medium used in the present study included 1% of fetal
calf serum (Materials and methods). Fetal calf serum has been
shown to contain BMP4 activity, which may impact the course
of hESC differentiation (Xu et al., 2002; Ying et al., 2003;
Kodaira et al., 2006). However, 1% fetal calf serum in the basal
medium did not activate ID1, ID2, or ID3 (FIG. S2), all of which
are known target genes of BMP4 signaling in hESCs (Miyazono
and Miyazawa, 2002; López-Rovira et al., 2002). This suggests
that BMP4 activity in this serum-containing basal medium is
negligible. Thus, manipulation of Nodal/Activin signaling level
alone in the same basal medium was sufficient to drive the
differentiation toward the DE or NE lineage.
To further investigate the mode of cell differentiation
toward DE or NE, time courses of DE and NE marker
expression during 8 days of culture were examined. Tran-
script levels of the DE markers SOX17 and CXCR4 peaked at
day 6, while FOXA2 peaked at day 4 of culture with high
Activin A (Figure 1B). We further examined expression of
SOX17 protein by immunocytochemistry and FACS analysis
to assess the extent of DE induction under this culture
condition. Distinct nuclear staining was detected in approx-
imately 70–80% of cells at day 6 of high Activin A treatment
(Figure 1C). The number of SOX17-positive cells gradually
increased during 6 days of culture with high Activin A in a
manner similar to the profile of SOX17 transcript level (FIG.
S3). These results suggest that the majority of the cell
population was induced toward DE within 6 days of Activin Atreatment. Expression time course for NE induction by
SB431542 treatment was more variable among the marker
genes examined. PAX6 continued to rise throughout 8 days of
culture in the presence of SB431542 (Figure 1B). In contrast,
GBX2 expression peaked at day 6, which is similar to the
expression time course of the DE genes in response to Activin
A treatment. The transcript levels of NFH rose through days
2 and 4, slightly dropped on day 6, and rose again by day
8 (Figure 1B). PAX6 protein was detected in approximately
70–80% of cells at day 6 of SB431542 treatment, indicating
that NE induction was efficient under this culture condition
(Figure 1D). Thus, treatment of hESCs with high Activin A
and SB431542 were able to induce the expressions of DE and
NE markers, respectively, with distinct temporal profiles.
A total of 4 days of enhanced Nodal/Activin signaling
is required for induction of DE
While the expression of DE genes was robustly elevated after
6 days of culture with high Activin A, it is not clear whether
continuous presence of Activin A throughout the culture
period is required to upregulate the DE genes. Also unclear is
whether cells need to be exposed to high Activin A at
particular time points during 6 days of culture. To address
these questions, we designed 6 day-culture schemes with a
total of 2 days or 4 days of high Activin A treatment at
different time points, as outlined in the diagram (Figure 2A).
hESCs were cultured in the basal medium alone (as denoted
in white) or in the basal medium containing high Activin A (as
denoted in red). Significant upregulation of SOX17 and
FOXA2 (pb0.05) was observed when cells were treated with
high Activin A for a total of 4 days, regardless of at which
time points Activin A was present in the medium during
6 days of culture (Figure 2A). Namely, similar expression
levels of the DE genes were achieved by either initial 4 days
of Activin A followed by 2 days of no Activin A (4dAA-2dBM),
or initial 2 days of no Activin A followed by 4 days of Activin A
(2dBM-4dAA), or two rounds of 2 day Activin A treatment
separated by 2 days of no Activin A (2dAA-2dBM-2dAA). A
total of 4 days of Activin A treatment also elevated the
expression level of CXCR4 relative to that in the basal
medium (6dBM), although it was not statistically significant
(p=0.057) for 2dAA-2dBM-2dAA. In contrast, there was
essentially no significant upregulation of all DE genes by
2 days of Activin A treatment (2dAA-4dBM, 4dBM-2dAA, or
2dBM-2dAA-2dBM) as compared to 6 days of basal medium
(6dBM), except for a slight but significant (pb0.01) upregu-
lation of CXCR4 by 2 days of Activin A treatment after day 4
(4dBM-2dAA) (Figure 2A). These results overall suggest that a
total of 4 days of high Activin A treatment was sufficient and
necessary for upregulation of DE markers.
Enhancement of Nodal/Activin signaling for 4 days
promotes commitment toward DE and diminishes
competence toward NE
As shown above, 4 days of high Activin A treatment was
sufficient to upregulate the DE genes even when Activin A
was not added in the culture medium for 2 days. However, it
is possible that endogenous Nodal/Activin signaling is still
active at a low level even in the absence of exogenous
Figure 1 Enhancement and inhibition of Activin signaling in hESCs promotes DE and NE, respectively. (A) qRT-PCR analysis showing the
expression levels of the DEmarkers (SOX17, FOXA2 and CXCR4) and NEmarkers (PAX6,GBX2 and NFH) after 6 days of culture in 4 different
media: mT = mTeSR, BM = the basal medium, AA = Activin A (50 ng/mL) in the basal medium, and SB = SB431542 (10 μM) in the basal
medium. For the DE and NE markers, the expression levels in AA and SB are used for standardization, respectively (i.e., relative
expression=100). (B) qRT-PCR analysis showing temporal expression profiles of the DE and NE markers over 8 days of culture in different
media. In each experiment (AA compared with BM for the DE markers, and SB compared with BM for the NE markers), the highest
expression level is used for standardization. (C) Immunocytochemistry showing expression of DE marker SOX17 in hESCs cultured for
6 days in the basal medium containing high Activin A. (D) Immunocytochemistry showing expression of NE marker PAX6 in hESCs cultured
for 6 days in the basal medium containing SB431542. All nuclei are visualized by staining with DAPI in (C) and (D).
492 K.L. Jaremko, Y. MarikawaActivin A. Thus, to further delineate the role of Nodal/Activin
signaling in developmental commitment and competence
toward the DE lineage, another set of experiments were
designed, in which the endogenous Nodal/Activin signaling
was forcefully inhibited with SB431542 (as denoted in blue)
before or after Activin A treatment (Figure 2B). Basically,
we conducted the same 2 or 4 days total of high Activin A
treatment during 6 days of culture, with the addition of
SB431542 on days treated with the basal medium alone in the
previous scheme (compare Figs. 2A and B). As demonstrated
by robust upregulation of SOX17, FOXA2 and CXCR4, the initial
4 days of enhanced Nodal/Activin signaling was sufficient to
promote the DE lineage even when Nodal/Activin signaling
was inhibited afterward for 2 days (4dAA-2dSB). This suggests
that hESCs are already committed to the DE lineage after
4 days of Nodal/Activin signaling enhancement. However,when cells were treated with SB431542 prior to a total of
4 days of high Activin A treatment (i.e., 2dSB-4dAA or 2dAA-
2dSB-2dAA), the activation of SOX17 and FOXA2 expression
was essentially abrogated. The response of CXCR4 expression
to SB431542 treatment was not as distinct as those of SOX17
and FOXA2, implicating that the regulation of CXCR4 by
Nodal/Activin signaling may be different from the other two
DE markers (see Discussion). Nonetheless, these results
suggest that inhibition of Nodal/Activin signaling for 2 days
with SB431542 compromises competence of hESCs to DE.
When Nodal/Activin signaling was enhanced for 4 days
initially, however, cells did not downregulate DE markers
and were thus committed toward DE.
We then inquired how the competence of hESCs to give rise
to NE would be affected with respect to their commitment
toward the DE lineage. To address this question, we first
Figure 2 Four days of enhanced Nodal/Activin signaling promotes commitment toward the DE lineage and impairs competence
toward the NE lineage. (A) Left: Schematic representation of the hESC culture scheme, in which cells are cultured for a total of 6 days
in the basal medium containing high Activin A at different time points and durations. Right: qRT-PCR analysis showing expression
levels of the DE markers, SOX17, FOXA2, and CXCR4. In each experiment, the level in 6dAA (6 days of culture in the presence of high
Activin A) is used for standardization (i.e., relative expression=100). The expressions that are significantly different from that in
6dBM (6 days of culture in the basal medium alone) are marked with asterisks (* for pb0.05 and ** for pb0.01). (B) Left: Schematic
representation of the hESC culture scheme, in which cells are cultured for a total of 6 days in the basal medium containing high
Activin A or SB431542 at different time points and durations. Right: qRT-PCR analysis showing expression levels of the DE markers. In
each experiment, the level in 6dAA is used for standardization. The expressions that are significantly different from that in 6dBM are
marked with asterisks (* for pb0.05 and ** for pb0.01). (C) Left: Schematic representation of the hESC culture scheme, in which cells
are initially cultured for 2 days or 4 days in the presence or absence of high Activin A, and then cultured for 4 days with SB431542.
Right: qRT-PCR analysis showing expression levels of the NEmarkers, PAX6,GBX2, and NFH. In each experiment, the level in 4dBM-4dSB is
used for standardization. The expression levels are compared for statistical significance between the two treatments with the same total
duration of culture, that is, 2dBM-4dSB versus 2dAA-4dSB, and 4dBM-4dSB versus 4dAA-4dSB. Significant differences (pb0.05) aremarked
with an asterisk. (D) Left: Schematic representation of the hESC culture scheme, in which cells are cultured with SB431542 for different
durations (0, 2, 4, or 8 h), followed by 4 days of Activin A treatment. Right: qRT-PCR analysis showing expression levels of the DEmarkers.
In each experiment, the level in 4dAA is used for standardization. The expressions that are significantly different from that in 4dAA are
markedwith asterisks (pb0.01). BM = the basal medium, AA = Activin A (50 ng/mL) in the basal medium, and SB = SB431542 (10 μM) in the
basal medium.
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by 4 days of SB431542 treatment, and then examined the
expression levels of the three NEmarkers, PAX6,GBX2, andNFH
(Figure 2C). When hESCs were pre-treated with Activin A for
2 days (2dAA-4dSB), the expressions of the NEmarkers were not
significantly reduced compared to the control (2dBM-4dSB),
although the PAX6 level appeared to be slightly lower (not
statistically significant). This indicates that hESCswere still able
to give rise to NE in response to the inhibition of Nodal/Activin
signaling even when signaling was enhanced for 2 days prior
to inhibition. In contrast, when pre-treated with Activin A for
4 days (4dAA-4dSB), the expression levels of all three NE
markers were significantly reduced compared to the control
(4dBM-4dSB) (Figure 2C). These results suggest that hESCs lose
the competence toward NE when they become committed
toward the DE lineage by 4 days of enhanced Nodal/Activin
signaling.The competence to give rise to DE is impaired after
2 days, but not 1 day, of Nodal/Activin
signaling inhibitionThe loss of DE competence by the inhibition of Nodal/Activin
signaling occurred more rapidly than the loss of NE
competence by the activation of Nodal/Activin signaling
(i.e., the former took 2 days while the latter took 4 days).
This implicates that DE competence is more fragile than
NE competence. To assess how quickly DE competence is
impaired, we inhibited Nodal/Activin signaling for much
shorter durations, namely 2, 4, and 8 h and tested whether
DE competence would be affected. After the short duration
of SB431542 treatment, hESCs were cultured with high
Activin A for 4 days and the expression levels of DE markers
SOX17 and FOXA2 were examined. Surprisingly, the upregu-
lation of these DE marker genes was significantly diminished
even with just 2 h of SB431542 treatment (Figure 2D). This
result implicates either that the DE competence is extreme-
ly fragile to the inhibition of Nodal/Activin signaling or that
treatment with SB431542 irreversibly impaired its targets,
namely ALK4, 5 and 7, and thus compromised activation ofFigure 3 Two days of Nodal/Activin signaling inhibition compromis
expression levels of Nodal/Activin signaling target genes, LEFTY1 and N
pharmacological inhibitors (SB431542, LY364947, A-83-01, SB505124
(50 ng/mL) for 2 h. The expression level in the no-inhibitor con
expression=100). The expressions that are significantly lower than tha
analysis showing the expression levels of Nodal/Activin signaling
pharmacological inhibitors for 2 h. The expression level in the no-inhi
that are significantly lower than that in 2hrBM aremarkedwith asterisk
scheme, in which cells are cultured with LY364947 for 1 day or 2 days,
showing expression levels of the DE markers, SOX17, FOXA2, an
standardization. The expressions that are significantly lower than th
asterisks (* for pb0.05 and ** for pb0.01). (D) Left: Schematic represen
LY364947 for 1 day or 2 days, followed by 4 h of Activin A treatment. Rig
signaling target genes. The level in 1dBM-4hrAA or 2dBM-4hrAA is used
culture scheme, in which cells are cultured with LY364947 for 1 day or
analysis showing expression levels of the mesendoderm markers, BRAC
2dBM-2dAA is used for standardization. The expressions that are signifi
are marked with asterisks (pb0.01).Nodal/Activin signaling even after removal of the inhibitor
from the culture medium.
To test the latter possibility, we examined whether
Activin A treatment after SB431542 can still activate the
expression of LEFTY1 and NODAL, known target genes of
Nodal/Activin signaling in hESCs (Besser, 2004). hESCs were
first cultured for 2 h in the absence or presence of SB431542
(i.e., 2hrBM or 2 hr[SB431542]), and then treated with Activin
A for 2 h (i.e., 2hrAA). The levels of LEFTY1 and NODAL were
significantly lower in 2 hr[SB431542]-2hrAA than in 2hrBM-
2hrAA (Figure 3A), indicating that Nodal/Activin signaling was
not effectively activated by Activin A after SB431542 removal.
The reduction in Nodal/Activin signaling was unlikely due to
residual SB431542 in the culture medium, because additional
washing before Activin A treatment did not fully restore the
activation of LEFTY1 and NODAL (FIG. S4). These results
suggest that inhibition of Nodal/Activin signaling by SB431542
is not immediately reversible after its removal. This finding
obscures the interpretation of the previous experiments (Figs.
2B,D), because SB431542might have irreversibly damaged the
machinery for Nodal/Activin signaling, rather than impacting
the developmental competence to give rise to DE.
To address this issue, we tested several other pharmaco-
logical inhibitors of Nodal/Activin signaling that are com-
monly used, with a hope to identify a reversible inhibitor, of
which impact on Nodal/Activin signaling can be abated after
removal from the culture medium. Treatment with 10 μM of
LY364947, A-83-01, SB505124, or SB525334 (Vogt et al.,
2011) robustly and equally downregulated the expression of
LEFTY1 and NODAL within 2 h (Figure 3B), confirming that all
of these compounds are potent inhibitors of Nodal/Activin
signaling in hESCs. After 2 h of inhibitor treatment, hESCs
were cultured with Activin A for 2 h, and examined for the
activation of LEFTY1 and NODAL. The expression levels of
these target genes in response to Activin A treatment were
significantly lower in A-83-01-treated, SB505124-treated,
and SB525334-treated cells, as compared to the control
(2hrBM-2hrAA) (Figure 3A). This indicates that these in-
hibitors also compromised the Nodal/Activin signaling
machinery even after removal, similar to SB431542. In
striking contrast, however, the activation of LEFTY1 and
NODAL in LY364947-treated cells was as robust as in thees the competence toward DE. (A) qRT-PCR analysis showing the
ODAL, in cells that are initially treated for 2 h with one of the five
, SB525334; all at 10 μM), followed by treatment with Activin A
trol (2hrBM-2hrAA) is used for standardization (i.e., relative
t in 2hrBM-2hrAA are marked with asterisks (pb0.05). (B) qRT-PCR
target genes in cells that are treated with one of the five
bitor control (2hrBM) is used for standardization. The expressions
s (pb0.05). (C) Left: Schematic representation of the hESC culture
followed by 4 days of Activin A treatment. Right: qRT-PCR analysis
d CXCR4. The level in 1dBM-4dAA or 2dBM-4dAA is used for
e matching control (1dBM-4dAA or 2dBM-4dAA) are marked with
tation of the hESC culture scheme, in which cells are cultured with
ht: qRT-PCR analysis showing the expression levels of Nodal/Activin
for standardization. (E) Left: Schematic representation of the hESC
2 days, followed by 2 days of Activin A treatment. Right: qRT-PCR
HYURY (BRA), EOMES, GSC, and MIXL1. The level in 1dBM-2dAA or
cantly lower than the matching control (1dBM-2dAA or 2dBM-2dAA)
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is an effective and reversible inhibitor, and does not impair
the transduction of Nodal/Activin signaling after its remov-
al. Thus, LY364947 serves as an ideal tool to address ouroriginal question about how long hESCs retain DE compe-
tence when Nodal/Activin signaling is inhibited.
In order to address this question, hESCs were treated with
LY364947 for 1 day or 2 days (i.e., 1dLY or 2dLY), followed
496 K.L. Jaremko, Y. Marikawaby Activin A treatment for 4 days (i.e., 4dAA), and examined
for the activation of the DE markers. The expression levels of
SOX17, CXCR4, and FOXA2 in 1dLY-4dAA were similar to
those of the control, 1dBM-4dAA (Figure 3C). Thus, the DE
competence was not impaired after 1 day of inhibition of
Nodal/Activin signaling. In contrast, the levels of all the DE
markers in 2dLY-4dAA were significantly lower than those in
2dBM-4dAA (Figure 3C). Importantly, this loss of DE compe-
tence was not due to permanent impairment of the
machinery for Nodal/Activin signaling, as it was still intact
even after 2 days of LY364947 treatment, as demonstrated
by robust activation of LEFTY1 and NODAL in response to
Activin A treatment for 4 h (Figure 3D). These results suggest
that hESCs lose the DE competence after 2 days, but not
1 day, of Nodal/Activin signaling inhibition and that this
competence loss is not due to irreversible impairment of
Nodal/Activin signaling.
To gain further insight into how hESCs lose DE compe-
tence, we examined the expression of mesendoderm genes
in response to Activin A after LY364947 treatment. Mesen-
doderm is the common precursor of definitive endoderm and
mesoderm, which arises in the primitive streak during
embryogenesis (Rodaway and Patient, 2001; Tada et al.,
2005). Key mesendoderm genes, such as BRACHYURY (BRA),
GSC, and MIXL1, are activated in hESCs by Activin A
treatment, which temporarily precedes the activation of
DE genes (Chen et al., 1997; Labbé et al., 1998; D'Amour
et al., 2005; Yu et al., 2011). When hESCs were cultured with
LY364947 for 1 day prior to Activin A treatment for 2 days
(1dLY-2dAA), the expression levels of the mesendoderm
genes were as high as those of the control (1dBM-2dAA)
(Figure 3E). In contrast, their expression levels were
substantially diminished by 2 days of LY364947 treatment
(2dLY-2dAA) compared to the control (2dBM-2dAA), indicat-
ing that hESCs were no longer capable of activating the
mesendoderm genes in response to Activin A after 2 days of
Nodal/Activin signaling inhibition (Figure 3E). This result
raises the possibility that the loss of DE competence may be
due to the lack of mesendoderm formation.Downregulation of POU5F1 coincides with the loss of
the DE competence caused by Nodal/Activin signaling
inhibition
The above studies implicate that properties of hESCs are
dramatically altered with respect to the DE competence
between 1 day and 2 days of Nodal/Activin signaling inhibition.
To gain further insight into the molecular nature of this
alteration, we examined whether the expression levels of key
pluripotency regulators, namely POU5F1, NANOG, SOX2,
KLF4, PBX1 and ZFP42 (also known as REX1) (Ben-Shushan
et al., 1998; Loh et al., 2006; Boyer et al., 2005; Chan et al.,
2009), are affected by 1 day and/or 2 days of Nodal/Activin
signaling inhibition. The transcript levels of PBX1 and ZFP42
were largely unchanged during 2 days of LY364947 treatment,
although the level of ZPF42 was only slightly lowered
by LY364947 (Figure 4A). The transcript levels of KLF4 and
SOX2 were significantly elevated after 2 days of LY364947
treatment (Figure 4A). In contrast, LY364947 treatment
downregulated the expression of POU5F1 and NANOG. Thetranscript level of POU5F1 was essentially unchanged after
1 day of LY364947 treatment, while it was significantly
reduced after 2 days of treatment down to about 40% of the
level in the untreated control (Figure 4A). The transcript level
of NANOG was already decreased within 1 day of LY364947
treatment down to about 10% of the control (Figure 4A).
Downregulation of POU5F1 and NANOG by LY364947 was also
confirmed at the protein level by FACS analysis and immuno-
cytochemistry (FIG. S5).
Reduction in the POU5F1 and NANOG expression levels in
response to Nodal/Activin signaling inhibition is particularly
intriguing in light of several studies, which have suggested
potential involvement of these two genes in mesendoderm
formation in mouse ES cells, EC cells, and hESCs (Niwa et al.,
2000; Chambers et al., 2007; Stefanovic et al., 2009; Yu et al.,
2011; Marikawa et al., 2011; Thomson et al., 2011). Consistent
with these notions, the levels of POU5F1 and NANOG
transcripts were not decreased during the first 6 days of
DE differentiation culture, while they were distinctly down-
regulated during NE differentiation culture (Figure 4B).
Thus, the expression of these two pluripotency regulators
at a level similar to undifferentiated cells appears to be
compatible with the differentiation toward mesendoderm
and DE.
As shown above, the levels of POU5F1 and NANOG were
significantly reduced in 2 days of Nodal/Activin signaling
inhibition. However, it is possible that their expression levels
may be immediately restored upon activation of Nodal/Activin
signaling by Activin A, which would discredit the potential link
between their downregulation and the loss of DE competence.
Thus, we examined the expression levels of POU5F1 and
NANOG in those cells that were cultured with Activin A (for
4 h) after the treatment with LY364947 (for 1 day or 2 days).
The level of NANOG transcript was markedly elevated in
response to Activin A treatment (Figure 4C), even after 2 days
of pre-treatment with LY364947. In contrast, the level of
POU5F1 remained significantly lower than the basal level (in
mTeSR) after 4 h of Activin A treatment (Figure 4C). Thus,
reduction in the expression of POU5F1 appears to correlate
well with the loss of DE competence that is caused by 2 days of
Nodal/Activin signaling inhibition.Discussion
In this study, we investigated the mode of developmental
commitment and competence toward the DE and NE lineages
in hESCs in response to changes in Nodal/Activin signaling
activity. Four days of enhanced Nodal/Activin signaling was
sufficient to commit hESCs toward the DE lineage, as the
inhibition of signaling afterward could no longer suppress the
expression of DE genes. Concomitantly, competence toward
the NE lineage was significantly impaired by prior treatment
with high Activin A for 4 days. Thus, the commitment to DE
was associated with the loss of competence to NE, suggesting
that the developmental potential of hESCs is critically altered
after 4 days of enhanced Nodal/Activin signaling. Interesting-
ly, the key regulators of developmental pluripotency, POU5F1
and NANOG, were still robustly expressed after 4 days of
Activin A treatment, indicating that the loss of NE competence
was not due to lack of expression of these pluripotency
regulators. However, it is possible that DE-specific genes that
Figure 4 Downregulation of POU5F1 is associated with the impairment in DE competence. (A) qRT-PCR analysis showing the expression
levels of the pluripotency regulators, PBX1, ZFP42, KLF4, SOX2, POU5F1, and NANOG, in cells that are treated with LY364947 (10 μM) for
1 day (1dLY) or 2 days (2dLY). The level in the mTeSR control is used for standardization (i.e., relative expression=100). The expressions
that are significantly different from that in mTeSR are marked with asterisks (* for pb0.05 and ** for pb0.01). (B) qRT-PCR analysis
showing temporal expression profiles of POU5F1 and NANOG over 8 days of culture in differentmedia. In each experiment, the expression
level at day 0 is used for standardization. BM = the basal medium, AA = Activin A in the basal medium, and SB = SB431542 in the basal
medium. (C) Left: Schematic representation of the hESC culture scheme, in which cells are cultured with LY364947 for 1 day or 2 days,
followed by 4 h of Activin A treatment. Right: qRT-PCR analysis showing the expression levels of POU5F1 andNANOG. The level inmTeSR is
used for standardization.
497Competence and commitment to definitive endodermwere activated by 4 days of Activin A treatment, namely
SOX17, could impose inhibitory effects on the pluripotency
regulators and the expression of NE-specific genes. A study
showed that POU5F1 has a dual function by working with both
SOX2 and SOX17 to maintain pluripotency and to promote the
mesendoderm lineage, respectively (Stefanovic et al., 2009).
POU5F1 binds to SOX17, and both together occupy the promoter
of endoderm genes, such as HEX and SOX17 itself. Elevation of
SOX17 by enhanced Nodal/Activin signaling may deprive
POU5F1 from operating with SOX2, which is involved in both
pluripotencymaintenance aswell as NE development (Avilion et
al., 2003; Li et al., 2005; Zappone et al., 2000; Papanayotou et
al., 2008; Archer et al., 2011; Thomson et al., 2011). Another
possibility is that the expression levels or epigenetic status of
genes important for NE differentiation may be altered after
4 days of enhanced Nodal/Activin signaling. For example,
Nodal/Activin signaling, alongwith NANOGand POU5F1, repress
the expression of SIP1 (Smad-interacting protein 1; also known
as ZEB2), which is essential for NE differentiation (Chng et al.,
2010). It is possible that the extended enhancement of Nodal/
Activin signaling may result in permanent interference with the
expression of NE regulators, such as SIP1, thereby inhibiting
competence toward NE.A moderate level of Nodal/Activin signaling is essential for
themaintenance of pluripotency in hESCs (Beattie et al., 2005;
James et al., 2005; Vallier et al., 2005). In the present study,
hESCs were maintained in a chemically defined medium,
mTeSR1, which contains TGFβ1 to activate Nodal/Activin
signaling (Ludwig et al., 2006). Our basal medium itself was
not supplemented with any growth factors to activate Nodal/
Activin signaling. Nonetheless, a low level of Nodal/Activin
signaling was likely to be active in the basal medium, owing to
the endogenous expression of NODAL in hESCs (Vallier et al.,
2004). This endogenous low level of Nodal/Activin signaling
may be sufficient to sustain the expression of pluripotency
regulators POU5F1 for up to 4 days and NANOG for up to 2 days
(Figure 4B). This is in striking contrast to the basal medium
supplemented with SB431542, which downregulated POU5F1
and NANOGmuch more rapidly (Figure 4B). However, the level
of Nodal/Activin signaling in the basal mediumwas possibly too
low to prevent the appearance of NE features, specifically the
expression of PAX6, as it was gradually upregulated in the basal
medium alone (Figure 1B). PAX6 has been shown to act as the
NE fate determinant in hESCs, as its expression is both
necessary and sufficient to induce NE differentiation (Zhang
et al., 2010). Regardless, the other NEmarkers,GBX2 and NFH,
498 K.L. Jaremko, Y. Marikawawere not upregulated in the basal medium even after 8 days of
culture, raising the possibility that expression of PAX6 alone is
not enough to activate these NE markers under this culture
condition.
In the present study, we tested five different pharmacolog-
ical agents that are commonly used as selective inhibitors of
Nodal/Activin signaling, namely SB431542, LY364947, A-83-01,
SB505124, and SB525334 (Inman et al., 2002; Callahan et al.,
2002; Laping et al., 2002; DaCosta Byfield et al., 2004; Laping et
al., 2007; Sawyer et al., 2003; Peng et al., 2005; Tojo et al.,
2005; Vogt et al., 2011), and found that only LY364947 was fully
reversible such that Nodal/Activin signaling was activated
efficiently after its removal from the culture medium. To our
knowledge, this is the first study to demonstrate this unique
characteristic of LY364947. It is unclear which chemical and/or
physical characteristics of LY364947 enable effective and swift
reversal of its negative impact on Nodal/Activin signaling. It
may simply be due to its smallermolecularweight (MW=272.30)
compared to the other inhibitors, namely SB431542 (MW=
384.39), A-83-01 (MW=421.52), SB505124 (MW=335.40), and
SB525334 (MW=343.42), that is, LY364947 may diffuse out of
the cells much more easily than the others. Regardless, this
unique property of LY364947 allowed us in the present study to
investigate critically the duration of Nodal/Activin signaling
inhibition that impairs the developmental competence toward
DE, without sustained impairment on Nodal/Activin signaling.
Compared to SOX17 and FOXA2, the response of CXCR4 to
Nodal/Activin signaling was not substantially impaired by the
inhibition of Nodal/Activin signaling (Figs. 2B,D). This is
interesting in light of a recent study that identified conserved
triple SOX17-binding sites within the CXCR4 proximal enhanc-
er, which implicates that the expression of CXCR4 is under the
control of SOX17 (Katoh and Katoh, 2010). Nonetheless,
CXCR4 was still expressed when the expression of SOX17 was
significantly downregulated after the inhibition of Nodal/
Activin signaling. It is possible that even with reduced SOX17
expression, CXCR4 expression was maintained by POU5F1 as
well as Activin A, because the CXCR4 enhancer also contains a
POU-binding site and SMAD-binding sites (Katoh and Katoh,
2010).
We only used inhibition of Nodal/Activin signaling to
induce NE in this study, because the main purpose of the
study was to investigate specifically how Nodal/Activin
signaling controls developmental commitment and compe-
tence toward DE and NE. Several studies have shown that the
inhibition of Nodal/Activin signaling alone is indeed suffi-
cient to induce NE lineages in hESCs (Smith et al., 2008;
Patani et al., 2009). However, regulation of other signaling
pathways is also involved in the promotion of NE develop-
ment in hESCs, namely the activation of FGF signaling and
the inhibition of BMP signaling (Chambers et al., 2009; Chng
et al., 2010). Additionally, enhancement of other pathways,
such as Wnt signaling can promote differentiation toward
the DE lineage (Payne et al., 2011; Mayhew and Wells, 2010;
Bone et al., 2011). Future studies are essential to determine
how these other signaling pathways can impact the commit-
ment and competence toward DE and NE. For example, does
the activation of FGF signaling or inhibition of BMP signaling
impair the competence toward DE? Also, does the activation of
Wnt signaling impair competence toward NE? These studies
should shed light on themolecular nature of themachinery that
is responsible for the maintenance of DE and NE competence.A recent study shows that SIP1 controls cell-fate decisions
between the NE and mesendoderm lineages in hESCs (Chng
et al., 2010). SIP1 antagonizes TGFβ family signaling via direct
interaction with MH2 domains of SMAD1/2/3. The expression of
SIP1 is inhibited by the pluripotency regulators, POU5F1 and
NANOG, which suppresses NE differentiation. On the other
hand, SIP1 expression is activated by SOX2, which limits the
mesendoderm-inducing effects of Nodal/Activin signaling.
Inhibition of Nodal/Activin signaling results in the upregulation
of SIP1, which further interferes with this signaling through
positive-feedback to promote NE lineage development (Chng
et al., 2010). In addition, the repression of SIP1 expression by
POU5F1 and NANOG is relieved when these pluripotency
regulators are downregulated by the inhibition of Nodal/
Activin signaling. Is the loss of DE competence by LY364947
treatment, as shown in the present study, due to the inhibition
of Nodal/Activin signaling by SIP1? This is unlikely the case,
because even after LY364947 treatment, hESCs were still able
to activate LEFTY1 and NODAL, the downstream target genes
of Nodal/Activin signaling, in response to Activin A (Figure 3D).
Therefore, the cause of DE competence loss cannot be
attributed to impaired transduction of Nodal/Activin signaling.
Among six pluripotency regulators examined, only NANOG
and POU5F1 were downregulated by 2 days of LY364947
treatment, which impaired DE competence. NANOG is a direct
target of Nodal/Activin signaling, and the maintenance
of its expression requires active Nodal/Activin signaling (Xu
et al., 2008; Chambers et al., 2007; Vallier et al., 2009; Yu
et al., 2011). Furthermore, NANOG is essential to maintain DE
competence in hESCs, because the knockdown of NANOG
expression by RNAi compromises the ability of hESCs to become
DE in response to enhanced Nodal/Activin signaling (Vallier
et al., 2009). Nonetheless, the loss of the DE competence by
LY364947 treatment is unlikely caused by downregulation of
NANOG for the following two reasons. First, either 1 day or
2 days of LY364947 treatment caused substantial downregula-
tion of NANOG, while only 2 days of treatment abrogated DE
competence. Second, the expression of NANOG was almost
immediately restored by Activin A treatment even after 2 days
of LY364947 treatment. Thus, downregulation of NANOG does
not always correlate with the loss of DE competence. On the
other hand, however, the downregulation of POU5F1 cor-
relates with the abrogation of DE competence. Specifically,
both the level of POU5F1 and the DE competence were
significantly reduced only after 2 days, but not 1 day, of
LY364947 treatment. In addition, the expression of POU5F1
remained low after 2 days of LY364947 treatment even when
Nodal/Activin signaling was activated afterward with Activin
A. Repression of POU5F1 in human and mouse ESCs results
in differentiation to trophectoderm (Nichols et al., 1998;
Matin et al., 2004; Zaehres et al., 2005; Babaie et al., 2007),
while overexpression of POU5F1 causes expression of mesen-
doderm genes, including Sox17, Hex, and T (Niwa et al., 2000;
Stefanovic et al., 2009). Recent studies with mouse ESCs and
P19 embryonal carcinoma cells suggested that Pou5f1 is also
required for mesendoderm differentiation, as knockdown of
Pou5f1 impaired the upregulation of Brachyury in response to
Wnt/β-catenin signaling activation (Thomson et al., 2011;
Marikawa et al., 2011). Thus, downregulation of POU5F1 may
be contributing to the loss of DE competence, although other
factors may also be involved. Future studies should be designed
to identify molecular alterations at the transcriptional,
499Competence and commitment to definitive endodermprotein, and epigenetic levels that occur in response to 2 days,
but not 1 day, of Nodal/Activin signaling inhibition, which lead
to a loss of competence to the DE lineage.Materials and methods
hESC culture
hESCs (H9; WiCell Research Institute, Madison, WI) were
maintained on plates coated with growth factor-reduced
Matrigel (BD Biosciences, San Jose, CA) in the serum-free,
defined media, mTeSR1 (Stemcell Technologies, Vancouver,
BC), which was changed daily. For routine passaging (every
3–4 days), cells were harvested by incubating with Dispase
(1 mg/mL; Invitrogen, Carlsbad, CA) at 37 °C for approximate-
ly 5 min and 1:4 to 1:6 portion was plated into 6-well plates
pre-coated with Matrigel. Because chromosome abnormalities
have often been observed for late passages (p80–p115) in H9
cells (Smith et al., 2008), only earlier passages (p40–p60) were
used for the present study.hESC differentiation
H9 cells were plated in 4-well plates pre-coated with Matrigel,
and cultured for 3–4 days inmTeSR1 until colonies grew to 50–
70% confluency. For the differentiation protocols, medium
was replaced with the basal medium (DMEM-F12, 1% fetal calf
serum, 1× non-essential amino acids [Sigma-Aldrich, St. Louis,
MO], and 1×2-mercaptoethanol [Millipore, Billerica, MA]). For
differentiation to definitive endoderm (DE), medium was
replaced with the basal medium supplemented with 50 ng/mL
of recombinant Activin A (R&D Systems, Minneapolis, MN). For
differentiation to neuroectoderm (NE), cells were placed in
the basal medium with 10 μM SB431542 (EMD Biosciences, San
Diego, CA). For both differentiation protocols, media were
changed every 2 days unless otherwise noted.RNA extraction and quantitative polymerase chain
reaction
After maintenance or differentiation culture, cells were
lysed with Trizol Reagent (Sigma-Aldrich), and total RNA was
isolated according to the manufacturer's instructions. cDNA
was synthesized from total RNA, using oligo dT(18) primer
and M-MLV Reverse Transcriptase (Promega, Madison, WI).
Real-time PCR was performed using iCycler Thermal Cycler
with MyiQ Single Color Real-Time PCR Detection System (Bio-
Rad, Hercules, CA). cDNA was amplified using iQ SYBR Green
Supermix (Bio-Rad) with the following conditions: the initial
denaturation at 94 °C (5 min) followed by up to 45 cycles of
94 °C (15 s), 60 °C (20 s), and 72 °C (40 s). The primer
sequences for reverse transcription‐polymerase chain reac-
tion (RT-PCR) are shown in Supporting Information. GAPDH
levels were used to normalize the expression levels of all
other genes. All experiments were conducted using at least 3
independent sets of samples (biological replicates), and data
are presented as average±standard deviation, and statisti-
cal comparisons were performed using Student's t-test.Immunocytochemistry
Cells were fixed for 30 min in 4% paraformaldehyde (PFA) in
PBS (phosphate-buffered saline) at room temperature and
permeabilized with 0.5% Triton-X100 in PBS for 15 min at
room temperature. After blocking in 5% bovine serum albumin
(BSA) in PBS, cells were incubated overnight with anti-SOX17
(AF1924; R&D Systems), anti-PAX6 (PRB-278P; Covance Inc.,
Princeton, NJ), anti-OCT4 (C-10; Santa Cruz), or anti-NANOG
(AF1997; R&D Systems) primary antibody in 0.1% Tween-20 in
PBS (PBSw) at 4 °C. Cells were washed and incubated with
Alexa488-conjugated or Alexa546-conjugated secondary anti-
bodies (Invitrogen) in PBSw for 2 h at room temperature. Cells
were then stained with 4′,6-diamidino-2-phenylindole (DAPI)
and examined with an Axiovert200 fluorescence microscope
(Carl Zeiss).
Fluorescence activated cell sorting (FACS) analysis
Cells were dissociated to single cells in 0.25% Trypsin-EDTA for
10 min at 37 °C, fixed in 4% PFA in PBS for 20 min at room
temperature, and permeabilized with 0.5% Triton-X100 in PBS
for 20 min at room temperature. After blocking in 5% BSA in PBS,
cells were incubated overnight with either anti-SOX17, anti-
OCT4, or anti-NANOG primary antibody in PBSw at 4 °C. Cells
were washed and incubated with Alexa488-conjugated second-
ary antibodies (Invitrogen) in PBSw for 3 h at room temperature.
Cells were then washed, sorted with a FACSAria III, and
analyzed using the FACSDiva software (BD Biosciences).
Supplementary materials related to this article can be
found online at http://dx.doi.org/10.1016/j.scr.2012.04.
002.
Author contributions
K.L.J. and Y.M.: conception and design; Y.M.: financial support;
K.L.J.: collection and assembly of data; K.L.J. and Y.M.: data
analysis and interpretation; K.L.J. and Y.M.: manuscript
writing; K.L.J. and Y.M.: final approval of manuscript.
Conflict of interest
The authors indicate no potential conflict of interest.
Acknowledgments
This work was supported by grants from the George F. Straub Trust
Fund of the Hawaii Community Foundation Medical Research Grant
(11ADVC-49271) and Johns Hopkins Center for Alternatives to
Animal Testing Grant (#2012-11) to Y.M. FACS analysis was
conducted at the Institute for Biogenesis Research FACS Core
Facility, which was supported by the COBRE grants from the
National Center for Research Resources (5P20RR024206-05) and
the National Institute of General Medical Sciences (8P20GM103457-
05) from the National Institutes of Health. The authors thank Dr.
Phillip Davy and Natsumi Takahashi for their assistance with our
FACS analysis. The authors also thank Dr. Vernadeth B. Alarcon and
Dana Ann A. Tamashiro at the Institute for Biogenesis Research for
technical assistance and encouragement throughout the study.
K.L.J. thanks the Cell and Molecular Biology Graduate Program at
the University of Hawaii for support.
500 K.L. Jaremko, Y. MarikawaReferences
Amit, M., Shakiri, C., Margulets, V., Itskovitz-Eldor, J., 2004.
Feeder-layer and serum-free culture of human embryonic stem
cells. Biol. Reprod. 70, 837–845.
Archer, T.C., Jin, J., Casey, E.S., 2011. Interaction of Sox1, Sox2, Sox3
and Oct4 during primary neurogenesis. Dev. Biol. 350, 429–440.
Avilion, A.A., Nicolis, S.K., Pevny, L.H., Perez, L., Vivian, N., Lovell-
Badge, R., 2003. Multipotent cell lineages in early mouse develop-
ment depend on SOX2 function. Genes Dev. 17, 126–140.
Babaie, Y., Herwig, R., Greber, B., Brink, T.C., Wruck, W., Groth,
D., Lehrach, H., Burdon, T., Adjaye, J., 2007. Analysis of Oct4-
dependent transcriptional networks regulating self-renewal and
pluripotency in human embryonic stem cells. Stem Cells 25,
500–510.
Beattie, G.M., Lopez, A.D., Bucay, N., Hinton, A., Firpo, M.T., King,
C.C., Hayek, A., 2005. Activin A maintains pluripotency of human
embryonic stem cells in the absence of feeder layers. Stem Cells
23, 489–495.
Ben-David, U., Benvenisty, N., 2011. The tumorigenicity of human
embryonic and induced pluripotent stem cells. Nat. Rev. Cancer
11, 268–277.
Ben-Shushan, E., Thompson, J.R., Gudas, L.J., Bergman, Y., 1998.
Rex-1, a gene encoding a transcription factor expressed in the
early embryo, is regulated via Oct-3/4 and Oct-6 binding to an
octamer site and a novel protein, Rox-1, binding to an adjacent
site. Mol. Cell. Biol. 18, 1866–1878.
Besser, D., 2004. Expression of Nodal, Lefty-A, and Lefty-B in
undifferentiated human embryonic stem cells requires activa-
tion of Smad2/3. J. Biol. Chem. 279, 45076–45084.
Blum, B., Benvenisty, N., 2008. The tumorigenicity of human
embryonic stem cells. Adv. Cancer Res. 100, 133–158.
Bone, H.K., Nelson, A.S., Goldring, C.E., Tosh, D., Welham, M.J.,
2011. A novel chemically directed route for the generation of
definitive endoderm from human embryonic stem cells based on
inhibition of GSK-3. J. Cell Sci. 124, 1992–2000.
Borowiak, M., Maehr, R., Chen, S., Chen, A.E., Tang, W., Fox, J.L.,
Schreiber, S.L., Melton, D.A., 2009. Small molecules efficiently
direct endodermal differentiation of mouse and human embry-
onic stem cells. Cell Stem Cell 4, 348–358.
Boyer, L.A., Lee, T.I., Cole, M.F., Johnstone, S.E., Levine, S.S.,
Zucker, J.P., Guenther, M.G., Kumar, R.M., Murray, H.L.,
Jenner, R.G., Gifford, D.K., Melton, D.A., Jaenisch, R., Young,
R.A., 2005. Cell 122, 947–956.
Brons, I.G.M., Smithers, L.E., Trotter, M.W.B., Rugg-Gunn, P., Sun,
B., de Sousa, Chuva, Lopes, S.M., Howlett, S.K., Clarkson, A.,
Ahrlund-Richter, L., Pedersen, R.A., Vallier, L., 2007. Derivation
of pluripotent epiblast stem cells from mammalian embryos.
Nature 448, 191–196.
Callahan, J.F., Burgess, J.L., Fornwald, J.A., Gaster, L.M., Harling,
J.D., Harrington, F.P., Heer, J., Kwon, C., Lehr, R., Mathur, A.,
Olson, B.A., Weinstock, J., Laping, N.J., 2002. Identification of
novel inhibitors of the transforming growth factor β1 (TGF-β1)
Type 1 Receptor (ALK5). J. Med. Chem. 45, 999–1001.
Camus, A., Perea-Gomez, A., Moreau, A., Collignon, J., 2006.
Absence of Nodal signaling promotes precocious neural differ-
entiation in the mouse embryo. Dev. Biol. 295, 743–755.
Chambers, I., Silva, J., Colby, D., Nichols, J., Nijmeijer, B.,
Robertson, M., Vrana, J., Jones, K., Grotewold, L., Smith, A.,
2007. Nanog safeguards pluripotency and mediates germline
development. Nature 450, 1230–1235.
Chambers, S.M., Fasano, C.A., Papapetrou, E.P., Tomishima, M.,
Sadelain, M., Studer, L., 2009. Highly efficient neural conversion
of human ES and iPS cells by dual inhibition of SMAD signaling.
Nat. Biotechnol. 27, 275–280.
Chan, K.K., Zhang, J., Chia, N.Y., Chan, Y.S., Sim, H.S., Tan, K.S.,
Oh, S.K., Ng, H.H., Choo, A.B., 2009. KLF4 and PBX1 directlyregulate NANOG expression in human embryonic stem cells.
Stem Cells 27, 2114–2125.
Chen, X., Weisberg, E., Fridmacher, V., Watanabe, M., Naco, G.,
Whitman, M., 1997. Smad4 and FAST-1 in the assembly of
activin-responsive factor. Nature 389, 85–89.
Chng, Z., Teo, A., Pedersen, R.A., Vallier, L., 2010. SIP1 mediates
cell-fate decisions between neuroectoderm and mesendoderm in
human pluripotent stem cells. Cell Stem Cell 6, 59–70.
D'Amour, K.A., Agulnick, A.D., Eliazer, S., Kelly, O.G., Kroon, E.,
Baetge, E.E., 2005. Efficient differentiation of human embryonic
stem cells to definitive endoderm. Nat. Biotechnol. 23, 1534–1541.
DaCosta Byfield, S., Major, C., Laping, N.J., Roberts, A.B., 2004. SB-
505124 is a selective inhibitor of transforming growth factor-
beta type I receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 65,
744–752.
Fong, C.Y., Gauthaman, K., Bongso, A., 2010. Teratomas from
pluripotent stem cells: a clinical hurdle. J. Cell. Biochem. 111,
769–781.
Gearhart, J., 1998. New potential for human embryonic stem cells.
Science 282, 1061–1062.
Gilbert, S., 2010. Developmental Biology, 9th ed. Sinauer Associ-
ates, Sunderland, MA.
Hu, B.Y., Weick, J.P., Yu, J., Ma, L.X., Zhang, X.Q., Thomson, J.A.,
Zhang, S.C., 2010. Neural differentiation of human induced
pluripotent stem cells follows developmental principles but with
variable potency. Proc. Natl. Acad. Sci. U. S. A. 107, 4335–4340.
Inman, G.J., Nicolás, F.J., Callahan, J.F., Harling, J.D., Gaster,
L.M., Reith, A.D., Laping, N.J., Hill, C.S., 2002. SB-431542 is a
potent and specific inhibitor of transforming growth factor-β
superfamily type I Activin receptor-like kinase (ALK) receptors
ALK4, ALK5, and ALK7. Mol. Pharmacol. 62, 65–74.
James, D., Levine, A.J., Besser, D., Hemmati-Brivanlou, A., 2005.
TGFβ/Activin/Nodal signaling is necessary for the maintenance
of pluripotency in human embryonic stem cells. Development
132, 1273–1282.
Katoh, M., Katoh, M., 2010. Integrative genomic analyses of CXCR4:
transcriptional regulation of CXCR4 based on TGFbeta, Nodal,
Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and
GFI1 transcription factors. Int. J. Oncol. 36, 415–420.
Kodaira, K., Imada, M., Goto, M., Tomoyasu, A., Fukuda, T.,
Kamijo, R., Suda, T., Higashio, K., Katagiri, T., 2006. Purifica-
tion and identification of a BMP-like factor from bovine serum.
Biochem. Biophys. Res. Commun. 345, 1224–1231.
Labbé, E., Silvestri, C., Hoodless, P.A., Wrana, J.L., Attisano, L.,
1998. Smad2 and Smad3 positively and negatively regulate TGF
beta-dependent transcription through the forkhead DNA-binding
protein FAST2. Mol. Cell. 2, 109–120.
Laping, N.J., Grygielko, E., Mathur, A., Butter, S., Bomberger, J.,
Tweed, C., Martin, W., Fornwald, J., Lehr, R., Harling, J.,
Gaster, L., Callahan, J.F., Olson, B.A., 2002. Inhibition of
transforming growth factor (TGF)-beta1-induced extracellular
matrix with a novel inhibitor of the TGF-beta type I receptor
kinase activity: SB-431542. Mol. Pharmacol. 62, 58–64.
Laping, N.J., Everitt, J.I., Frazier, K.S., Burgert, M., Portis, M.J.,
Cadacio, C., Gold, L.I., Walker, C.L., 2007. Tumor-specific
efficacy of transforming growth factor-beta RI inhibition in Eker
rats. Clin. Cancer Res. 13, 3087–3099.
Li, X., Du, Z., Zarnowska, E.D., Pankratz, M., Hansen, L.O., Pearce,
R.A., Zhang, S., 2005. Specification of motoneurons from human
embryonic stem cells. Nat. Biotechnol. 23, 215–221.
Loh, Y.H., Wu, Q., Chew, J.L., Vega, V.B., Zhang, W., Chen, X.,
Bourque, G., George, J., Leong, B., Liu, J., Wong, K.Y., Sung, K.W.,
Lee, C.W., Zhao, X.D., Chiu, K.P., Lipovich, L., Kuznetsov, V.A.,
Robson, P., Stanton, L.W., Wei, C.L., Ruan, Y., Lim, B., Ng, H.H.,
2006. The Oct4 and Nanog transcription network regulates plur-
ipotency in mouse embryonic stem cells. Nat. Genet. 38, 431–440.
López-Rovira, T., Chalaux, E., Massaqué, J., Rosa, J.L., Ventura, F.,
2002. Direct binding of Smad1and Smad4 to two distinct motifs
501Competence and commitment to definitive endodermmediates bone morphogenetic protein-specific transcriptional
activation of Id1 gene. J. Biol. Chem. 277, 3176–3185.
Lowry, W.E., Plath, K., 2008. The many ways to make an iPS cell.
Nat. Biotechnol. 26, 1246–1248.
Ludwig, T.E., Levenstein, M.E., Jones, J.M., Berggren, W.T.,
Mitchen, E.R., Frane, J.L., Crandall, L.J., Daigh, C.A., Conard,
K.R., Piekarczyk, M.S., Llanas, R.A., Thomson, J.A., 2006.
Derivation of human embryonic stem cells in defined conditions.
Nat. Biotechnol. 24, 185–187.
Marikawa, Y., Tamashiro, D.A., Fujita, T.C., Alarcon, V.B., 2011.
Dual roles of Oct4 in the maintenance of mouse P19 embryonal
carcinoma cells: as negative regulator of Wnt/β-catenin signal-
ing and competence provider for Brachyury induction. Stem Cells
Dev. 20, 621–633.
Matin, M.M., Walsh, J.R., Gokhale, P.J., Draper, J.S., Bahrami,
A.R., Morton, I., Moore, H.D., Andrews, P.W., 2004. Specific
knockdown of Oct4 and β2-microglobulin expression by RNA
interference in human embryonic stem cells and embryonic
carcinoma cells. Stem Cells 22, 659–668.
Mayhew, C.N., Wells, J.M., 2010. Converting human pluripotent
stem cells into β-cells: recent advances and future challenges.
Curr. Opin. Organ Transplant. 15, 54–60.
Miyazono, K., Miyazawa, K., 2002. Id: a target of BMP signaling. Sci.
STKE. pe40.
Nichols, J., Zevnik, B., Anastassiadis, K., Niwa, H., Klewe-Nebenius,
D., Chambers, I., Scholer, H., Smith, A., 1998. Formation of
pluripotent stem cells in the mammalian embryo depends on the
POU transcription factor Oct4. Cell 95, 379–391.
Niwa, H., Miyazaki, J., Smith, A.G., 2000. Quantitative expression
of Oct-3/4 defines differentiation, dedifferentiation or self-
renewal of ES cells. Nat. Genet. 24, 372–376.
Papanayotou, C., Mey, A., Birot, A., Saka, Y., Boast, S., Smith, J.C.,
Samarut, J., Stern, C.D., 2008. A mechanism regulating the onset of
Sox2 expression in the embryonic neural plate. PLoS Biol. 6, e2.
Park, I., Zhao, R., West, J.A., Yabuuchi, A., Huo, H., Ince, T.A.,
Lerou, P.H., Lensch, M.W., Daley, G.Q., 2008. Reprogramming of
human somatic cells to pluripotency with defined factors.
Nature 451, 141–146.
Patani, R., Compston, A., Puddifoot, C.A., Wyllie, D.J.A.,
Hardingham, G.E., Allen, N.D., Chandran, S., 2009. Activin/
Nodal inhibition alone accelerates highly efficient neural
conversion from human embryonic stem cells and imposes a
caudal positional identity. PLoS One 4, e7327.
Payne, C., King, J., Hay, D., 2011. The role of Activin/Nodal and
Wnt signaling in endoderm formation. Vitam. Horm. 85,
207–216.
Peng, S.B., Yan, L., Xia, X., Watkins, S.A., Brooks, H.B., Beight, D.,
Herron, D.K., Jones, M.L., Lampe, J.W., McMillen, W.T., Mort,
N., Sawyer, J.S., Yingling, J.M., 2005. Kinetic characterization
of novel pyrazole TGF-beta receptor I kinase inhibitors and their
blockade of the epithelial–mesenchymal transition. Biochemis-
try 44, 2293–2304.
Pera, M.F., Reubinoff, B., Trounson, A., 2000. Human embryonic
stem cells. J. Cell Sci. 113, 5–10.
Rodaway, A., Patient, R., 2001. Mesendoderm: an ancient germ
layer? Cell 105, 169–172.
Sawyer, J.S., Anderson, B.D., Beight, D.W., Campbell, R.M., Jones,
M.L., Herron, D.K., Lampe, J.W., McCowan, J.R., McMillen,
W.T., Mort, N., Parsons, S., Smith, E.C., Vieth, M., Weir, L.C.,
Yan, L., Zhang, F., Yingling, J.M., 2003. Synthesis and activity of
new aryl- and heteroaryl-substituted pyrazole inhibitors of the
transforming growth factor-beta type I receptor kinase domain.
J. Med. Chem. 46, 3953–3956.
Schier, A.F., 2003. Nodal signaling in vertebrate development.
Annu. Rev. Cell Dev. Biol. 19, 589–621.
Smith, J.R., Vallier, L., Lupo, G., Alexander, M., Harris, W.A.,
Pedersen, R.A., 2008. Inhibition of Activin/Nodal signalingpromotes specification of human embryonic stem cells into
neuroectoderm. Dev. Biol. 313, 107–117.
Stefanovic, S., Abboud, N., Désilets, S., Nury, D., Cowan, C.,
Pucéat, M., 2009. Interplay of Oct4 with Sox2 and Sox17: a
molecular switch from stem cell pluripotency to specifying a
cardiac fate. J. Cell Biol. 186, 665–673.
Sulzbacher, S., Schroeder, I.S., Truong, T.T., Wobus, A.M., 2009.
Activin A-induced differentiation of embryonic stem cells into
endoderm and pancreatic progenitors—the influence of differ-
entiation factors and culture conditions. Stem Cell Rev. 5,
159–173.
Tada, S., Era, T., Furusawa, C., Sakurai, H., Nishikawa, S.,
Kinoshita, M., Nakao, K., Chiba, T., Nishikawa, S., 2005.
Characterization of mesendoderm: a diverging point of the
definitive endoderm and mesoderm in embryonic stem cell
differentiation culture. Development 132, 4363–4374.
Takahashi, K., Yamanaka, S., 2006. Induction of pluripotent stem
cells from mouse embryonic and adult fibroblast cultures by
defined factors. Cell 126, 663–676.
Thompson, T.B., Cook, R.W., Chapman, S.C., Jardetzky, T.S.,
Woodruff, T.K., 2004. Beta A versus beta B: is it merely a matter
of expression? Mol. Cell. Endocrinol. 225, 9–17.
Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A.,
Swiergiel, J.J., Marshall, V.S., Jones, J.M., 1998. Embryonic
stem cell lines derived from human blastocysts. Science 282,
1145–1147.
Thomson, M., Liu, S.J., Zou, L.N., Smith, Z., Meissner, A.,
Ramanathan, S., 2011. Pluripotency factors in embryonic stem
cells regulate differentiation into germ layers. Cell 145,
875–889.
Tojo, M., Hamashima, Y., Hanyu, A., Kajimoto, T., Saitoh, M.,
Miyazono, K., Node, M., Imamura, T., 2005. The ALK-5 inhibitor
A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal
transition by transforming growth factor-beta. Cancer Sci. 96,
791–800.
Valdimarsdottir, G., Mummery, C., 2005. Functions of the TGFβ
superfamily in human embryonic stem cells. APMIS 113, 773–789.
Vallier, L., Reynolds, D., Pedersen, R.A., 2004. Nodal inhibits
differentiation of human embryonic stem cells along the
neuroectodermal default pathway. Dev. Biol. 275, 403–421.
Vallier, L., Alexander, M., Pedersen, R.A., 2005. Activin/Nodal and
FGF pathways cooperate to maintain pluripotency of human
embryonic stem cells. J. Cell Sci. 118, 4495–4509.
Vallier, L., Mendjan, S., Brown, S., Chng, Z., Teo, A., Smithers,
L.E., Trotter, M.W., Cho, C.H., Martinez, A., Rugg-Gunn, P.,
Brons, G., Pedersen, R.A., 2009. Activin/Nodal signaling main-
tains pluripotency by controlling Nanog expression. Development
136, 1339–1349.
Vogt, J., Traynor, R., Sapkota, G.P., 2011. The specificities of small
molecule inhibitors of the TGFβ and BMP pathways. Cell. Signal.
23, 1831–1842.
Waddington, C.H., 1940. Organisers and genes. Cambridge Univer-
sity Press, Cambridge UK.
Wang, P., Rodriguez, R.T., Wang, J., Ghodasara, A., Kim, S.K.,
2011. Targeting SOX17 in human embryonic stem cells creates
unique strategies for isolating and analyzing developing endo-
derm. Cell Stem Cell 8, 335–346.
Wassarman, K.M., Lewandoski, M., Campbell, K., Joyner, A.L.,
Rubenstein, J.L., Martinez, S., Martin, G.R., 1997. Specification
of the anterior hindbrain and establishment of a normal mid/
hindbrain organizer is dependent on Gbx2 gene function.
Development 124, 2923–2934.
Waters, S.T., Wilson, C.P., Lewandoski, M., 2003. Cloning and
embryonic expression analysis of the mouse Gbx1 gene. Gene
Expr. Patterns 3, 313–317.
Wolpert & Tickle, 2010. Principles of Development, 4th ed. Oxford
University Press, Oxford, UK.
502 K.L. Jaremko, Y. MarikawaXu, R.H., Chen, X., Li, D.S., Li, R., Addicks, G.C., Glennon, C.,
Zwaka, T.P., Thomson, J.A., 2002. BMP4 initiates human
embryonic stem cell differentiation to trophoblast. Nat. Bio-
technol. 20, 1261–1264.
Xu, R., Sampsell-Barron, T.L., Gu, F., Root, S., Peck, R.M., Pan, G.,
Yu, J., Antosiewicz-Bourget, J., Tian, S., Stewart, R., Thomson,
J.A., 2008. NANOG is a direct target of TGFbeta/activin-mediated
SMAD signaling in human ESCs. Cell Stem Cell 3, 196–206.
Ying, Q.L., Nichols, J., Chambers, I., Smith, A., 2003. BMP induction of
Id proteins suppresses differentiation and sustains embryonic stem
cell self-renewal in collaboration with STAT3. Cell 115, 281–292.
Yu, J., Thomson, J.A., 2008. Pluripotent stem cell lines. Genes Dev.
22, 1987–1997.
Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J.,
Frane, J.L., Tian, S., Nie, J., Jonsdottir, G.A., Ruotti, V.,
Stewart, R., Slukvin, I.I., Thomson, J.A., 2007. Induced
pluripotent stem cell lines derived from human somatic cells.
Science 318, 1917–1920.
Yu, P., Pan, G., Yu, J., Thomson, J.A., 2011. FGF2 sustains NANOG
and switches the outcome of BMP4-induced human embryonic
stem cell differentiation. Cell Stem Cell 8, 326–334.Zaehres, H., Lensch, M.W., Daheron, L., Stewart, S.A., Itskovitz-
Eldor, J., Daley, G.Q., 2005. High-efficiency RNA interference in
human embryonic stem cells. Stem Cells 23, 299–305.
Zappone, M.V., Galli, R., Catena, R., Meani, N., De Biasi, S., Mattei,
E., Tiveron, C., Vescovi, A.L., Lovell-Badge, R., Ottolenghi, S.,
Nicolis, S.K., 2000. Sox2 regulatory sequences direct expression
of a (beta)-geo transgene to telencephalic neural stem cells and
precursors of the mouse embryo, revealing regionalization of
gene expression in CNS stem cells. Development 127, 2367–2382.
Zhang, X., Huang, C.T., Chen, J., Pankratz, M.T., Xi, J., Li, J.,
Yang, Y., LaVaute, T.M., Li, X., Ayala, M., Bondarenko, G.I.,
Du, Z., Jin, Y., Golos, T.G., Zhang, S., 2010. Pax6 is a human
neuroectoderm cell fate determinant. Cell Stem Cell 7,
90–100.
Zhou, J., Su, P., Li, D., Tsang, S., Duan, E., Wang, F., 2010. High-
efficiency induction of neural conversion in hESCs and hiPSCs
with a single chemical inhibitor of TGF-β superfamily receptors.
Stem Cells 28, 1741–1750.
Zhu, W.Z., Van Biber, B., Laflamme, M.A., 2011. Methods for the
derivation and use of cardiomyocytes from human pluripotent
stem cells. Methods Mol. Biol. 767, 419–431.
